1. Furuta H, Yamada M, Nagashima T, Matsuda S, Nagayasu K, Shirakawa H, Kaneko S. Increased expression of glutathione peroxidase 3 prevents tendinopathy by suppressing oxidative stress. Front Pharmacol, 14:1137952 (2023) DOI: 10.3389/fphar.2023.1137952
2. Zhou Z, Nagashima T, Toda C, Kobayashi M, Suzuki T, Nagayasu K, Shirakawa H, Asai S, Kaneko S. Vitamin D supplementation is effective for olanzapine-induced dyslipidemia. Front Pharmacol, 14:1135516 (2023) DOI: 10.3389/fphar.2023.1135516
3. Yamamoto H, Kayanuma G, Nagashima T, Toda C, Nagayasu K, Kaneko S. Early detection of adverse drug reaction signals by association rule mining using large-scale administrative claims data. Drug Saf (2023) DOI: 10.1007/s40264-023-01278-4
4. Nagaoka K, Asaoka N, Nagayasu K, Shirakawa H, Kaneko S. Enhancement of adenosine A2A signaling improves dopamine D2 receptor antagonist-induced dyskinesia via beta-arrestin signaling. Front Neurosci, 16:1082375 (2023) DOI: 10.3389/fnins.2022.1082375
5. Nozawa K, Suzuki T, Kayanuma G, Yamamoto H, Nagayasu K, Shirakawa H, Kaneko S. Lisinopril prevents bullous pemphigoid induced by dipeptidyl peptidase 4 inhibitors via the Mas receptor pathway. Front Immunol, 13:1084960 (2023) DOI: 10.3389/fimmu.2022.1084960
6. Zhou Z, Nagayasu K, Shirakawa H, Kaneko S. Specific cellular effects of low bortezomib concentrations on purified cultures of Schwann cells, satellite glial cells, macrophages, and dorsal root ganglion neurons. Biol Pharm Bull, 46:102-110 (2023) DOI: 10.1248/bpb.b22-00668
7. Nagaoka K, Nagayasu K, Shirakawa H, Kaneko S: Acetaminophen improves tardive akathisia induced by dopamine D2 receptor antagonists. J Pharmacol Sci, 151:9-16 (2023) DOI: 10.1016/j.jphs.2022.10.006
8. Kuronuma K, Susai N, Kuroita T, Yamamoto H, Yoshioka T, Kaneko S, Chiba H: Analysis of real-world data and a mouse model indicates that pirfenidone causes pellagra. ERJ Open Res, 8:00245-2022 (2022) DOI: 10.1183/23120541.00245-2022
9. Hatakama H, Asaoka N, Nagayasu K, Shirakawa H, Kaneko S: A selective serotonin reuptake inhibitor ameliorates obsessive-compulsive disorder-like perseverative behavior by attenuating 5-HT2C receptor signaling in the orbitofrontal cortex. Neuropharmacology. 206:108926 (2022) DOI: 10.1016/j.neuropharm.2021.108926
10. Esaki H, Sasaki Y, Nishitani N, Kamada H, Mukai S, Ohshima Y, Nakada S, Ni X, Deyama S, Kaneda K: Role of 5-HT1A receptors in the basolateral amygdala on 3,4-methylenedioxymethamphetamine-induced prosocial effects in mice. Eur J Pharmacol, 946:175653 (2023) DOI: 10.1016/j.ejphar.2023.175653.